February 2, 2021 | Targeted Therapies in Oncology

Can CDK4/6 Inhibitors Be Optimized for Breast Cancer?

February 25, 2021

Clinical Articles

Can treatment with inhibitors of cyclindependent kinases 4 and 6 be optimized for patients with breast cancer? This remains an open question 6 years after the first approval of a CDK4/6 inhibitor, palbociclib.

Can BiTE Molecules Make Off-the-Shelf Immuno-Oncology a Reality?

February 15, 2021

Clinical Articles

In hematologic malignancies, a new class of molecules is emerging that may ultimately offer clinical benefits comparable to those chimeric antigen receptor T-cell therapies while reducing some of the negatives associated with them.